StockNow
Calendar
Log in
U.S. Markets

Merck (MRK) says, for Keytruda, expects moderating growth as it approaches peak revenues for certain approved indications and the German market to be impacted by policy dynamics

ORIGINAL · NewsquawkMerck (MRK) says, for Keytruda, expects moderating growth as it approaches peak revenues for certain approved indications and the German market to be impacted by policy dynamicsRead originalHide original

Anticipates underlying operating expenses to increase mid- to high-single digits in 2027.

StockNow breaking-news AI analysis

Merck expects Keytruda growth to moderate for certain approved indications, cites policy dynamics affecting Germany, and anticipates mid- to high-single-digit underlying operating-expense growth in 2027.

News detail

Anticipates underlying operating expenses to increase mid- to high-single digits in 2027.

1 stocks
MRKMerck & Co., Inc.$144.32Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump is reportedly seriously considering resuming military strikes against Iran shortly after the US midterms if diplomacy fails, while the US remains engaged in negotiations over a temporary peace deal, Semafor reports

Geopolitics

Iran's IRGC Navy claims three tankers struck naval mines, exploded and caught fire while travelling through an unauthorised southern route of the Strait of Hormuz over the past 24 hours, with the vessels subsequently abandoned

U.S. Markets

[MARKET UPDATE] Alphabet (GOOGL) -10.6% and Microsoft (MSFT) +4% in the pre-market following results

GOOGLGOOGMSFT